Gene/NN
Expression/NN
Analysis/NN
for/IN
Statin-induced/JJ
Cytotoxicity/NN
from/IN
Rat/NN
Primary/JJ
Hepatocytes/NNS
./.
====================
Statins/NNS
are/VBP
competitive/JJ
inhibitors/NNS
of/IN
hydroxy3methyl/NN
glutaryl/NN
coenzyme/NN
A/NN
(/(
HMG-CoA/NN
)/)
reductase/NN
and/CC
used/VBN
most/JJS
frequently/RB
to/TO
reduce/VB
plasma/NN
cholesterol/NN
levels/NNS
and/CC
to/TO
decrease/VB
cardiovascular/JJ
events/NNS
./.
====================
However/RB
,/,
statins/NNS
also/RB
have/VBP
been/VBN
reported/VBN
to/TO
have/VB
undesirable/JJ
side/JJ
effects/NNS
such/JJ
as/IN
myotoxicity/JJ
and/CC
hepatotoxicity/NN
associated/VBN
with/IN
their/PRP$
intrinsic/JJ
efficacy/NN
mechanisms/NNS
./.
====================
Clinical/JJ
studies/NNS
recurrently/RB
reported/VBD
that/IN
statin/NN
therapy/NN
elevated/JJ
the/DT
level/NN
of/IN
liver/NN
enzymes/NNS
such/JJ
as/IN
ALT/NN
and/CC
AST/NN
in/IN
patients/NNS
suggesting/VBG
possible/JJ
liver/NN
toxicity/NN
due/JJ
to/TO
statins/NNS
./.
====================
This/DT
observation/NN
has/VBZ
been/VBN
drawn/VBN
great/JJ
attention/NN
since/IN
statins/NNS
are/VBP
the/DT
most/JJS
prescribed/VBN
drugs/NNS
and/CC
statintherapy/NN
was/VBD
extended/VBN
to/TO
a/DT
larger/JJR
number/NN
of/IN
high-risk/JJ
patients/NNS
./.
====================
Here/RB
we/PRP
employed/VBD
rat/NN
primary/JJ
hepatocytes/NNS
and/CC
microarray/NN
technique/NN
to/TO
understand/VB
underlying/VBG
mechanism/NN
responsible/JJ
for/IN
statin-induced/JJ
liver/NN
toxicity/NN
on/IN
cell/NN
level/NN
./.
====================
We/PRP
isolated/VBD
genes/NNS
whose/WP$
expressions/NNS
were/VBD
commonly/RB
modulated/VBN
by/IN
statin/NN
treatments/NNS
and/CC
examined/VBN
their/PRP$
biological/JJ
functions/NNS
./.
====================
It/PRP
is/VBZ
of/IN
interest/NN
that/IN
those/DT
genes/NNS
have/VBP
function/NN
related/JJ
to/TO
response/NN
to/TO
stress/NN
in/IN
particular/JJ
immunity/NN
and/CC
defense/NN
in/IN
cells/NNS
./.
====================
Our/PRP$
study/NN
provided/VBD
the/DT
basic/JJ
information/NN
on/IN
cellular/JJ
mechanism/NN
of/IN
statininduced/JJ
cytotoxicity/NN
and/CC
may/MD
serve/VB
for/IN
finding/NN
indicator/NN
genes/NNS
of/IN
statin/NN
-induced/JJ
toxicity/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
Statins/NNS
are/VBP
competitive/JJ
hydroxy-3-methyl/NN
glutaryl/NN
coenzyme/NN
A/NN
(/(
HMG-CoA/NN
)/)
reductase/NN
inhibitors/NNS
that/IN
inhibit/VBP
the/DT
synthesis/NN
of/IN
cholesterol/NN
from/IN
mevalonic/JJ
acid/NN
and/CC
the/DT
drugs/NNS
most/JJS
frequently/RB
used/VBN
to/TO
reduce/VB
plasma/NN
cholesterol/NN
levels/NNS
and/CC
decrease/NN
cardiovascular/JJ
events/NNS
(/(
Abu/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
However/RB
,/,
the/DT
side/JJ
effects/NNS
associated/VBN
with/IN
the/DT
use/NN
of/IN
statins/NNS
have/VBP
been/VBN
highlighted/VBN
by/IN
the/DT
withdrawal/NN
of/IN
cerivastatin/JJ
from/IN
the/DT
market/NN
in/IN
2001/CD
(/(
Baycol/JJ
website/JJ
)/)
due/JJ
to/TO
its/PRP$
causing/VBG
a/DT
relatively/RB
high/JJ
incidence/NN
of/IN
myopathy/JJ
and/CC
rhabdomyolysis/NN
(/(
Yamazaki/NNP
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Together/RB
with/IN
myotoxicity/NN
,/,
there/EX
have/VBP
been/VBN
lingering/VBG
concerns/VBZ
regarding/VBG
statininduced/JJ
hepatotoxicity/NN
from/IN
the/DT
time/NN
of/IN
introduction/NN
of/IN
lovastatin/NN
in/IN
1987/CD
,/,
the/DT
first/JJ
member/NN
of/IN
the/DT
class/NN
./.
====================
Millions/NNS
of/IN
patients/NNS
have/VBP
now/RB
received/VBD
these/DT
drugs/NNS
./.
====================
Asymptomatic/JJ
increases/VBZ
in/IN
aminotransferase/NN
levels/NNS
develop/VBP
frequently/RB
(/(
Maddrey/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Since/IN
statins/NNS
inhibit/VBP
cholesterol/NN
synthesis/NN
in/IN
the/DT
liver/NN
much/RB
more/RBR
than/IN
in/IN
any/DT
other/JJ
tissue/NN
,/,
it/PRP
is/VBZ
not/RB
surprising/VBG
that/IN
elevations/NNS
in/IN
the/DT
liver/NN
enzymes/NNS
ALT/NN
and/CC
AST/NN
have/VBP
been/VBN
noted/VBN
since/IN
the/DT
first/JJ
clinical/JJ
trial/JJ
with/IN
lovastatin/NN
(/(
Hamelin/NN
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
In/IN
the/DT
case/NN
of/IN
statin/NN
therapy/NN
,/,
four/CD
types/NNS
of/IN
hepatic/JJ
syndromes/NNS
need/VBD
to/TO
be/VB
considered/VBN
;/:
acute/JJ
liver/NN
failure/NN
,/,
hepatitis/NN
,/,
cholestasis/NN
and/CC
transaminitis/NN
./.
====================
Initial/JJ
toxicology/NN
studies/NNS
in/IN
animals/NNS
suggested/VBD
that/IN
statins/NNS
may/MD
cause/VB
significant/JJ
liver/NN
problems/NNS
./.
====================
Although/IN
the/DT
usual/JJ
doses/NNS
of/IN
lovastatin/NN
did/VBD
not/RB
cause/VB
significant/JJ
liver/NN
injury/NN
,/,
when/WRB
given/VBN
in/IN
very/RB
high/JJ
dose/NN
they/PRP
caused/VBD
hepatocellular/JJ
necrosis/NN
in/IN
rabbits/NNS
(/(
Chalasani/NNP
,/,
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Similarly/RB
,/,
high/JJ
doses/NNS
of/IN
simvastatin/JJ
caused/VBD
hepatocellular/JJ
necrosis/NN
in/IN
guinea/NN
pig/NN
(/(
Chalasani/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
The/DT
liver/NN
injury/NN
in/IN
these/DT
animals/NNS
could/MD
be/VB
prevented/VBN
or/CC
reversed/VBD
with/IN
supplementing/VBG
animals/NNS
with/IN
mevalonate/JJ
suggesting/VBG
that/IN
depletion/NN
of/IN
mevalonate/JJ
or/CC
its/PRP$
downstream/JJ
metabolite/NN
might/MD
be/VB
responsible/JJ
for/IN
liver/NN
injury/NN
(/(
Chalasani/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
According/VBG
to/TO
adverse/JJ
effect/NN
reports/NNS
,/,
it/PRP
seemed/VBD
that/DT
all/DT
of/IN
these/DT
hepatic/JJ
adverse/JJ
effects/NNS
do/VBP
not/RB
have/VB
any/DT
significant/JJ
increase/NN
with/IN
statin/NN
therapy/NN
(/(
Abu/NNP
,/,
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
However/RB
,/,
as/IN
the/DT
use/NN
of/IN
lipid/NN
lowering/VBG
treatment/NN
including/VBG
statins/NNS
was/VBD
extended/VBN
to/TO
a/DT
larger/RBR
number/NN
of/IN
highrisk/JJ
patients/NNS
,/,
the/DT
potential/JJ
of/IN
statininduced/JJ
liver/NN
toxicity/NN
became/VBD
a/DT
major/JJ
concern/NN
for/IN
the/DT
safety/NN
profile/NN
of/IN
statins/NNS
./.
====================
Moreover/RB
,/,
a/DT
largescale/JJ
clinical/JJ
study/NN
encouraged/VBD
the/DT
use/NN
of/IN
statins/NNS
in/IN
a/DT
wide/JJ
range/NN
of/IN
patients/NNS
at/IN
varying/VBG
levels/NNS
of/IN
risk/NN
for/IN
cardiovascular/JJ
events/NNS
and/CC
independently/RB
of/IN
baseline/NN
cholesterol/NN
levels/NNS
(/(
Heart/NN
Protection/NN
Study/NN
,/,
2002/CD
,/,
Wilmshurst/JJ
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Taken/VBN
together/RB
,/,
it/PRP
seemed/VBD
that/DT
the/DT
most/JJS
concerning/VBG
issue/NN
for/IN
statin/NN
safety/NN
resides/VBZ
its/PRP$
potential/JJ
to/TO
cause/VB
acute/JJ
liver/NN
failure/NN
during/IN
wide/JJ
use/NN
of/IN
cholesterol/NN
lowering/VBG
therapy/NN
./.
====================
To/TO
address/VB
this/DT
concern/NN
,/,
it/PRP
would/MD
be/VB
helpful/JJ
to/TO
understand/VB
underlying/VBG
mechanism/NN
of/IN
statinin/NN
duced/JJ
toxicity/NN
using/VBG
a/DT
commonly/RB
used/VBN
system/NN
./.
====================
In/IN
the/DT
presented/VBN
work/NN
,/,
rat/NN
primary/JJ
hepatocytes/NNS
were/VBD
used/VBN
as/IN
a/DT
model/NN
system/NN
to/TO
assess/VB
statin-induced/JJ
toxicity/NN
by/IN
combining/VBG
microarray/NN
technique/NN
./.
====================
This/DT
effort/NN
will/MD
provide/VB
deeper/JJ
knowledge/NN
of/IN
the/DT
mechanisms/NNS
responsible/JJ
for/IN
the/DT
toxic/JJ
effects/NNS
of/IN
statins/NNS
along/IN
with/IN
putative/JJ
indicator/NN
genes/NNS
for/IN
statin/NN
-induced/JJ
toxicity/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
Rat/NN
primary/JJ
hepatocytes/NNS
were/VBD
isolated/VBN
using/VBG
a/DT
modified/JJ
method/NN
described/VBN
in/IN
elsewhere/JJ
(/(
Klaunig/NN
,/,
et/FW
al/JJ
./.
)/)
====================
and/CC
by/IN
Percoll/NN
centrifugation/NN
./.
====================
All/DT
media/NNS
and/CC
reagents/NNS
were/VBD
purchased/VBN
from/IN
Gibco/NN
(/(
NY/NN
,/,
USA/NN
)/)
unless/IN
mentioned/JJ
differently/RB
./.
====================
In/IN
brief/JJ
,/,
liver/NN
was/VBD
perfused/VBN
via/IN
portal/JJ
vein/NN
first/JJ
with/IN
Ca2＋/Mg2＋/JJ
free/JJ
Hank/NN
’/CD
s/NNS
balanced/JJ
salt/NN
solution/NN
(/(
HBSS-/NN
)/)
containing/VBG
0.5/CD
mM/NN
EGTA/NN
and/CC
10/CD
mM/NN
HEPES/NN
for/IN
2∼3/CD
min/NN
and/CC
then/RB
with/IN
HBSS/NN
with/IN
Ca2＋/Mg2＋/JJ
containing/VBG
10/CD
mM/NN
HEPES/NN
and/CC
0.5/CD
mg/ml/NN
collagenase/NN
(/(
Wako/NNP
)/)
for/IN
6∼7/CD
min/NN
at/IN
a/DT
flow/NN
rate/NN
of/IN
20/CD
ml/min/NN
./.
====================
Perfused/JJ
livers/NNS
were/VBD
isolated/VBN
,/,
decapsulated/VBD
and/CC
dispersed/JJ
in/IN
ice-cold/JJ
HBSS-/NN
./.
====================
Dispersed/VBN
cells/NNS
were/VBD
filtered/VBN
with/IN
100μm/CD
meshes/NNS
,/,
rinsed/JJ
and/CC
suspended/VBD
in/IN
icecold/JJ
50/CD
%/NN
(/(
v/v/LS
)/)
Percoll/NN
(/(
Amersham/NN
,/,
NJ/NNP
,/,
USA/NNP
)/)
and/CC
centrifuged/JJ
at/IN
50/CD
g/NN
for/IN
10/CD
min/NN
at/IN
4oC/NN
./.
====================
Hepatocytes/NNS
were/VBD
rinsed/VBN
and/CC
suspended/VBD
in/IN
Williams/NNS
’/CD
E/NN
culture/NN
media/NNS
supplemented/VBD
with/IN
10/CD
%/NN
(/(
v/v/LS
)/)
FCS/NN
,/,
2/CD
mM/NN
L-glutamate/NN
,/,
100/CD
U/ml/NN
penicillin/NN
,/,
100μg/ml/NN
streptomycin/NN
and/CC
10/CD
mM/NN
HEPES/NN
./.
====================
Cell/NN
cultures/NNS
showing/VBG
more/RBR
than/IN
80/CD
%/NN
viability/NN
,/,
based/VBN
on/IN
trypan/NN
blue/JJ
exclusion/NN
,/,
were/VBD
used/VBN
for/IN
further/JJ
experiment/NN
./.
====================
All/DT
cultures/NNS
were/VBD
maintained/VBN
at/IN
37oC/NN
in/IN
a/DT
watersaturated/JJ
5/CD
%/NN
CO2/NN
incubator/NN
and/CC
culture/NN
media/NNS
were/VBD
changed/VBN
every/RB
day/NN
./.
====================
Resazurin/NN
assay/NN
was/VBD
performed/VBN
to/TO
estimate/VB
cell/NN
toxicity/NN
of/IN
each/DT
drug/NN
using/VBG
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
Drugs/NNS
were/VBD
first/JJ
dissolved/JJ
in/IN
DMSO/NN
(/(
Sigma/NN
)/)
,/,
diluted/VBD
to/TO
the/DT
desired/VBN
concentration/NN
with/IN
water/NN
and/CC
administrated/VBN
to/TO
cells/NNS
for/IN
24/CD
hours/NNS
./.
====================
Then/RB
20μL/NN
of/IN
CellTiter-Blue/NN
(/(
Promega/NN
)/)
were/VBD
added/VBN
and/CC
the/DT
treated/VBN
cells/NNS
were/VBD
cultivated/VBN
in/IN
CO2/NN
incubator/NN
(/(
NuAire/JJ
,/,
US/NU-4350G/NN
)/)
for/IN
4/CD
hours/NNS
./.
====================
The/DT
level/NN
of/IN
toxicity/NN
was/VBD
observed/VBN
by/IN
optical/JJ
density/NN
using/VBG
microplate/JJ
reader/NN
(/(
SpectraMax/NN
plus/384/NN
,/,
Molecular/JJ
Devices/NNS
,/,
USA/NN
)/)
at/IN
wavelength/NN
of/IN
570/CD
nm/NN
./.
====================
The/DT
analytic/JJ
grade/NN
statins/NNS
were/VBD
purchased/VBN
from/IN
Sequoia/NN
Research/NN
Product/NN
(/(
Pangbourne/NN
,/,
UK/NN
)/)
./.
====================
The/DT
cells/NNS
were/VBD
treated/VBN
with/IN
the/DT
drugs/NNS
at/IN
designated/VBN
concentrations/NNS
(/(
EC/NN
,/,
1/25/CD
of/IN
LC20/NN
,/,
1/5/CD
of/IN
LC20/NN
and/CC
LC20/NN
)/)
for/IN
24/CD
hours/NNS
and/CC
lysed/VBD
with/IN
lysis/NN
buffer/NN
(/(
Invitrogen/NN
)/)
./.
====================
The/DT
RNAs/NNS
were/VBD
extracted/VBN
using/VBG
easyspinTM/JJ
Total/JJ
RNA/NN
Extraction/NN
Kit/NN
(/(
Invitrogen/NN
)/)
./.
====================
Extracted/JJ
RNAs/NNS
were/VBD
quantified/VBN
with/IN
spectrophotometer/NN
(/(
NanoDrop/NN
ND1000/CD
,/,
Rockland/CC
,/,
DE/NN
,/,
USA/NNP
)/)
,/,
and/CC
their/PRP$
purity/NN
was/VBD
estimated/VBN
by/IN
ratio/NN
of/IN
optical/JJ
density/NN
at/IN
230/260/CD
nm/NN
and/CC
260/280/CD
nm/NN
of/IN
wavelength/NN
./.
====================
Rat/NN
Genome/NN
230/CD
2.0/CD
GeneChips/NNS
(/(
Affymetrix/JJ
,/,
USA/NN
)/)
were/VBD
used/VBN
to/TO
profile/VB
gene/NN
expression/NN
modulation/NN
caused/VBD
by/IN
statins/NNS
in/IN
this/DT
experiment/NN
./.
====================
All/DT
procedures/NNS
were/VBD
followed/VBN
by/IN
the/DT
manufacturer/NN
’/CD
s/NNS
protocol/NN
described/VBN
in/IN
elsewhere/JJ
(/(
Ahn/NN
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
In/IN
short/JJ
,/,
the/DT
first/JJ
and/CC
second/JJ
strand/NN
cDNAs/NNS
were/VBD
synthesized/VBN
using/VBG
OneCycle/NN
cDNA/NN
Synthesis/NN
Kit/NN
1/CD
and/CC
Sample/JJ
Cleanup/NN
Module/JJ
1./LS
cRNAs/NNS
were/VBD
transcribed/VBN
from/IN
the/DT
synthesized/VBN
cDNA/NN
by/IN
In/FW
Vitro/NN
Transcription/NN
(/(
IVT/NN
)/)
Labeling/JJ
Kit/NN
1/CD
,/,
and/CC
fragmented/JJ
in/IN
5X/NN
fragmentation/NN
buffer/NN
at/IN
94oC/JJ
for/IN
35/CD
min/NN
./.
====================
The/DT
fragmented/JJ
cRNAs/NNS
were/VBD
hybridized/VBN
in/IN
the/DT
gene/NN
chips/NNS
using/VBG
Hybridization/NN
Control/NN
Kit/NN
1/CD
,/,
and/CC
incubated/VBN
at/IN
45oC/NN
for/IN
16/CD
hours/NNS
./.
====================
Then/RB
the/DT
chips/NNS
were/VBD
washed/VBN
and/CC
scanned/VBD
using/VBG
Affymetrix/JJ
GeneChip/NN
Scanner/NN
./.
====================
The/DT
microarray/NN
data/NNS
were/VBD
uploaded/VBN
to/TO
Genplex/NN
3.0/CD
program/NN
(/(
Istech/NNP
,/,
Korea/NN
)/)
and/CC
normalized/VBD
with/IN
MAS5/NN
,/,
Global/JJ
&/CC
scale/NN
method/NN
recommended/VBN
by/IN
Affymetrix/JJ
./.
====================
Further/RB
statistical/JJ
analyses/NNS
were/VBD
mainly/RB
performed/VBN
using/VBG
tools/NNS
provided/VBD
by/IN
Genplex/NN
program/NN
./.
====================
20We/DT
treated/VBN
rat/NN
primary/JJ
hepatocytes/NNS
with/IN
variety/NN
of/IN
concentration/NN
of/IN
test/NN
compounds/NNS
,/,
cerivastatin/NN
,/,
simvastatin/JJ
and/CC
lovastatin/NN
for/IN
24/CD
h/NN
to/TO
monitor/VB
their/PRP$
effects/NNS
on/IN
cell/NN
viability/NN
using/VBG
MTT/NN
assay/NN
./.
====================
Cerivastatin/NN
,/,
simvastatin/JJ
and/CC
lovastatin/NN
showed/VBD
significant/JJ
cell/NN
death/NN
and/CC
revealed/VBD
very/RB
typical/JJ
viability/NN
curves/NNS
with/IN
dosedependent/JJ
manner/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
LC20/NN
for/IN
each/DT
drug/NN
were/VBD
determined/VBN
as/IN
160μM/JJ
,/,
120μM/NN
and/CC
200μM/NN
respectively/RB
./.
====================
Cell/NN
viability/NN
test/NN
revealed/VBD
that/IN
simvastatin/JJ
caused/VBD
more/RBR
cytotoxicity/NN
than/IN
cerivastatin/NN
and/CC
lovastatin/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
This/DT
observation/NN
was/VBD
further/RBR
confirmed/VBD
by/IN
other/JJ
cell/NN
viability/NN
assay/NN
using/VBG
HepG2/NN
cells/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
where/WRB
simvastatin/JJ
also/RB
showed/VBD
higher/JJR
cytotoxicity/NN
than/IN
other/JJ
two/CD
statins/NNS
./.
====================
These/DT
in/IN
vitro/FW
observations/NNS
could/MD
not/RB
explain/VB
or/CC
reflect/VBP
exactly/RB
what/WP
happens/NNS
in/IN
clinical/JJ
use/NN
of/IN
statins/NNS
but/CC
still/RB
may/MD
arouse/VB
a/DT
question/NN
concerning/VBG
liver/NN
toxicity/NN
induced/VBD
by/IN
high/JJ
dose/NN
of/IN
statins/NNS
(/(
Bolego/NNP
,/,
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Based/VBN
on/IN
the/DT
cell/NN
viability/NN
test/NN
and/CC
bibliographical/JJ
searches/VBZ
,/,
the/DT
concentrations/NNS
of/IN
drugs/NNS
for/IN
the/DT
experiment/JJ
were/VBD
set/RB
at/IN
1/25/CD
fold/JJ
of/IN
LC20/NN
,/,
1/5/CD
fold/JJ
of/IN
LC20/NN
and/CC
LC20/NN
./.
====================
An/DT
additional/JJ
concentration/NN
(/(
0.5/CD
μM/NN
)/)
was/VBD
added/VBN
to/TO
the/DT
experiment/NN
to/TO
monitor/VB
the/DT
expression/NN
of/IN
genes/NNS
which/WDT
are/VBP
related/JJ
to/TO
the/DT
drug/NN
efficacy/NN
./.
====================
Using/VBG
four/CD
different/JJ
drug/NN
concentrations/NNS
and/CC
an/DT
untreated/JJ
control/NN
,/,
the/DT
effect/NN
of/IN
statins/NNS
on/IN
gene/NN
expression/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
was/VBD
assessed/VBN
by/IN
microarray/NN
experiments/NNS
./.
====================
Gene/NN
expression/NN
pattern/NN
of/IN
each/DT
drug/NN
was/VBD
analyzed/VBN
by/IN
Oneway/NN
ANOVA/NN
(/(
p/NN
value/NN
＜0.05/CD
)/)
with/IN
multiple/JJ
test/NN
correction/NN
(/(
BenjaminiHochberg/NN
FDR/NN
)/)
and/CC
showed/VBD
6,923/CD
,/,
2,688/CD
and/CC
4,383/CD
genes/NNS
significantly/RB
modulated/VBN
at/IN
least/JJS
one/CD
dose/NN
point/NN
of/IN
cerivastatin/JJ
,/,
lovastatin/NN
and/CC
simvastatin/JJ
treatment/NN
,/,
respectively/RB
./.
====================
To/TO
examine/VB
relations/NNS
between/IN
drug/NN
concentration/NN
and/CC
expression/NN
pattern/NN
,/,
hierarchical/JJ
clustering/NN
analysis/NN
(/(
HCA/NN
)/)
was/VBD
performed/VBN
for/IN
each/DT
drug/NN
treatment/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
HCA/NN
revealed/VBD
grouping/VBG
of/IN
gene/NN
expression/NN
profiles/NNS
along/IN
with/IN
the/DT
drug/NN
concentrations/NNS
and/CC
resulted/VBD
in/IN
four/CD
distinctive/JJ
hierarchical/JJ
clusters/NNS
in/IN
samples/NNS
instead/RB
of/IN
five/CD
clusters/NNS
due/JJ
to/TO
grouping/VBG
of/IN
1/25/CD
and/CC
1/5/CD
LC20/NN
samples/NNS
in/IN
the/DT
same/JJ
cluster/NN
./.
====================
Simvastatin/NN
and/CC
lovastatin/NN
treatment/NN
resulted/VBD
in/IN
grouping/VBG
EC/NN
and/CC
1/25/CD
LC20/NN
samples/NNS
into/IN
the/DT
same/JJ
cluster/NN
whereas/IN
cerivastatin/NN
treatment/NN
resulted/VBD
in/IN
grouping/VBG
1/25/CD
LC20/NN
and/CC
1/5/CD
LC20/NN
samples/NNS
into/IN
the/DT
same/JJ
cluster/NN
./.
====================
This/DT
observation/NN
can/MD
be/VB
explained/VBN
by/IN
the/DT
difference/NN
of/IN
clinical/JJ
doses/NNS
of/IN
the/DT
drugs/NNS
./.
====================
It/PRP
is/VBZ
known/VBN
that/IN
cerivastatin/NN
has/VBZ
more/RBR
potent/JJ
HMG-CoA/NN
reductase/NN
inhibition/NN
effect/NN
than/IN
other/JJ
statins/NNS
(/(
Stein/NN
et/FW
al./FW
,/,
1997/CD
)/)
./.
====================
Based/VBN
on/IN
the/DT
HCA/NN
results/NNS
,/,
it/PRP
seemed/VBD
that/DT
cerivastatin/NN
also/RB
caused/VBD
more/RBR
toxicity/NN
than/IN
other/JJ
two/CD
statins/NNS
at/IN
1/25/CD
LC20/NN
concentration/NN
./.
====================
Genes/NNS
whose/WP$
expressions/NNS
are/VBP
highly/RB
modulated/VBN
(/(
more/RBR
than/IN
two/CD
fold/JJ
)/)
by/IN
statin/NN
treatments/NNS
compared/VBN
with/IN
control/JJ
were/VBD
isolated/VBN
from/IN
each/DT
drug/NN
and/CC
dose/NN
conditions/NNS
after/IN
ANOVA/NN
test/NN
described/VBN
in/IN
the/DT
previous/JJ
section/NN
./.
====================
Table/JJ
1/CD
summarized/VBD
numbers/NNS
of/IN
genes/NNS
showed/VBD
more/RBR
two/CD
expression/NN
level/NN
changes/NNS
in/IN
treatment/NN
group/NN
./.
====================
In/IN
brief/JJ
,/,
cerivastatin/NN
seemed/VBN
to/TO
cause/VB
the/DT
most/JJS
serious/JJ
effect/NN
on/IN
gene/NN
expression/NN
in/IN
every/DT
dose/NN
conditions/NNS
./.
====================
Numbers/NNS
of/IN
significantly/RB
modulated/VBN
genes/NNS
by/IN
cerviastatin/JJ
were/VBD
greater/JJR
up/IN
to/TO
five/CD
fold/JJ
than/IN
lovastatin/NN
or/CC
simvastatin/JJ
depending/VBG
on/IN
the/DT
dose/NN
conditions/NNS
./.
====================
Since/IN
cerivastatin/JJ
showed/VBD
very/RB
similar/JJ
expression/NN
patterns/NNS
in/IN
1/25/CD
and/CC
1/5/CD
LC20/NN
doses/NNS
and/CC
relatively/RB
small/JJ
numbers/NNS
of/IN
DEG/NN
(/(
342/CD
and/CC
409/CD
genes/NNS
)/)
,/,
both/CC
dose/NN
groups/NNS
were/VBD
com/RB
bined/VBD
into/IN
a/DT
single/JJ
group/NN
(/(
Mid/NN
)/)
in/IN
the/DT
following/VBG
common/JJ
probe/NN
isolation/NN
,/,
KEGG/NN
and/CC
GO/NN
analysis/NN
./.
====================
In/IN
the/DT
contrary/JJ
,/,
lovastatin/NN
and/CC
simvastatin/JJ
revealed/VBD
similar/JJ
expression/NN
patterns/NNS
and/CC
small/JJ
DEG/NN
numbers/NNS
at/IN
EC/NN
and/CC
1/25/CD
LC20/NN
dose/NN
groups/NNS
and/CC
the/DT
two/CD
groups/NNS
were/VBD
combined/VBN
into/IN
a/DT
single/JJ
group/NN
(/(
Low/JJ
)/)
as/IN
well/RB
(/(
Fig/NN
./.
====================
2/CD
and/CC
Table/JJ
1/CD
)/)
./.
====================
As/IN
mentioned/VBN
in/IN
previous/JJ
section/NN
,/,
samples/NNS
were/VBD
grouped/VBN
as/IN
low/JJ
,/,
mid/JJ
and/CC
high/JJ
depending/VBG
on/IN
doses/NNS
and/CC
drugs/NNS
./.
====================
Using/VBG
Venn/JJ
diagram/NN
analysis/NN
,/,
commonly/RB
modulated/VBN
genes/NNS
by/IN
the/DT
drugs/NNS
at/IN
each/DT
dose/NN
were/VBD
isolated/VBN
./.
====================
As/IN
seen/VBN
Fig/NN
./.
====================
3/CD
,/,
16/CD
,/,
37/CD
and/CC
197/CD
genes/NNS
were/VBD
commonly/RB
presented/VBN
in/IN
low/JJ
,/,
mid/JJ
and/CC
high-dose/JJ
treatment/NN
respectively/RB
./.
====================
According/VBG
to/TO
KEGG/NN
pathway/NN
analysis/NN
(/(
Kanehisa/NN
and/CC
Goto/NNP
,/,
2000/CD
)/)
of/IN
these/DT
commonly/RB
modulated/VBN
genes/NNS
,/,
all/DT
three/CD
drugs/NNS
modulated/VBN
genes/NNS
related/JJ
to/TO
statin/NN
efficacy/NN
,/,
such/JJ
as/IN
biosynthesis/NN
of/IN
steroids/NNS
and/CC
fatty/JJ
acid/NN
metabolism/NN
,/,
at/IN
low/JJ
and/CC
mid/JJ
dose/NN
groups/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
But/CC
in/IN
high/JJ
dose/NN
treatment/NN
,/,
the/DT
drugs/NNS
modulated/VBN
genes/NNS
related/JJ
to/TO
cell/NN
cycle/NN
regulation/NN
and/CC
immune/JJ
response/NN
as/IN
well/RB
as/IN
genes/NNS
in/IN
fatty/JJ
acid/NN
metabolism/NN
./.
====================
This/DT
observation/NN
suggested/VBD
that/IN
the/DT
drugs/NNS
provoked/VBD
considerable/JJ
cytotoxicity/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
at/IN
high/JJ
dose/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
of/IN
these/DT
commonly/RB
modulated/VBN
genes/NNS
(/(
219/CD
in/IN
total/JJ
)/)
classified/VBN
samples/NNS
into/IN
three/CD
well/RB
defined/VBN
groups/NNS
such/JJ
as/IN
control/JJ
,/,
a/DT
group/NN
mixed/VBD
with/IN
low/JJ
and/CC
mid/JJ
doses/NNS
and/CC
a/DT
group/NN
of/IN
high/JJ
doses/NNS
./.
====================
Based/VBN
on/IN
these/DT
results/NNS
,/,
it/PRP
seemed/VBD
obvious/JJ
that/DT
statin/NN
treatment/NN
caused/VBD
toxic/JJ
effect/NN
and/CC
distinctive/JJ
gene/NN
modulation/NN
only/RB
at/IN
high/JJ
dose/NN
administration/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
To/TO
further/RBR
investigate/VB
which/WDT
biological/JJ
process/NN
were/VBD
affected/VBN
by/IN
statin/NN
treatment/NN
,/,
gene/NN
ontology/NN
(/(
GO/NN
)/)
analysis/NN
was/VBD
performed/VBN
by/IN
using/VBG
PANTHER/NN
program/NN
(/(
Protein/NN
ANalysis/NN
THrough/IN
Evolutionary/JJ
Relationships/NNS
Classification/NN
System/NN
,/,
www/RB
./.
====================
pantherdb/NN
./.
====================
org/NN
,/,
Mi/NNP
,/,
et/FW
al./FW
,/,
2005/CD
)/)
and/CC
enriched/JJ
GO/NN
terms/NNS
by/IN
statin/NN
treatment/NN
were/VBD
isolated/VBN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Gene/NN
Ontology/NN
analysis/NN
also/RB
showed/VBD
that/IN
the/DT
most/JJS
enriched/JJ
GO/NN
terms/NNS
by/IN
statin/NN
treatments/NNS
belonged/VBD
to/TO
cellular/JJ
metabolic/JJ
process/NN
and/CC
response/NN
to/TO
stress/NN
./.
====================
In/IN
particular/JJ
,/,
GO/NN
terms/NNS
related/JJ
to/TO
lipid/NN
,/,
fatty/JJ
acid/NN
and/CC
steroid/NN
metabolism/NN
were/VBD
highly/RB
over-represented/VBN
in/IN
most/JJS
treated/VBN
groups/NNS
representing/VBG
efficacy/NN
of/IN
statins/NNS
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
It/PRP
was/VBD
also/RB
remarkable/JJ
that/IN
GO/NN
terms/NNS
such/JJ
as/IN
immunity/NN
and/CC
defense/NN
and/CC
blood/NN
clotting/VBG
were/VBD
highly/RB
overrepresented/VBN
in/IN
high/JJ
dose/NN
groups/NNS
especially/RB
in/IN
cerivastatin/JJ
treatment/NN
groups/NNS
./.
====================
This/DT
observation/NN
suggested/VBD
that/IN
genes/NNS
in/IN
these/DT
GO/NN
terms/NNS
had/VBD
certain/JJ
relevance/NN
to/TO
cytotoxicity/NN
of/IN
the/DT
drugs/NNS
./.
====================
Based/VBN
on/IN
what/WP
we/PRP
observed/VBD
from/IN
DEG/NN
analysis/NN
and/CC
GO/NN
analysis/NN
of/IN
DEG/NN
,/,
we/PRP
tried/VBD
to/TO
isolate/VB
genes/NNS
which/WDT
may/MD
serve/VB
as/IN
indicator/NN
genes/NNS
for/IN
statin-induced/JJ
cytotoxicity/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
For/IN
this/DT
purpose/NN
,/,
genes/NNS
which/WDT
were/VBD
significantly/RB
modulated/VBN
by/IN
all/DT
three/CD
statins/NNS
and/CC
belonged/VBD
to/TO
response/NN
to/TO
stress/NN
were/VBD
isolated/VBN
as/IN
putative/JJ
markers/NNS
for/IN
statin-induced/JJ
cytotoxicity/NN
./.
====================
29/CD
probes/NNS
fit/NN
to/TO
these/DT
criteria/NNS
were/VBD
isolated/VBN
and/CC
subjected/VBD
to/TO
hierarchical/JJ
clustering/NN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
HCA/NN
showed/VBD
a/DT
very/RB
clear/JJ
clustering/NN
of/IN
genes/NNS
and/CC
samples/NNS
into/IN
two/CD
groups/NNS
./.
====================
First/RB
cluster/NN
was/VBD
composed/VBN
of/IN
low/JJ
dose/NN
treatments/NNS
of/IN
each/DT
drug/NN
such/JJ
as/IN
EC/NN
and/CC
1/25/CD
LC20/NN
dose/NN
groups/NNS
except/IN
for/IN
1/5/CD
LC20/NN
group/NN
of/IN
lovastatin/NN
treatment/NN
./.
====================
Second/RB
cluster/NN
was/VBD
mainly/RB
composed/VBN
of/IN
high/JJ
dose/NN
samples/NNS
such/JJ
as/IN
1/5/CD
LC20/NN
and/CC
LC20/NN
groups/NNS
except/IN
1/25/CD
LC20/NN
of/IN
cerivastatin/JJ
./.
====================
The/DT
last/JJ
cluster/NN
was/VBD
composed/VBN
of/IN
two/CD
high/JJ
dose/NN
samples/NNS
of/IN
cerivastatin/JJ
and/CC
simvastatin/JJ
./.
====================
Based/VBN
on/IN
the/DT
expression/NN
pattern/NN
of/IN
selected/VBN
genes/NNS
,/,
cerivastatin/NN
seemed/VBN
to/TO
have/VB
greater/JJR
effect/NN
on/IN
expression/NN
of/IN
cytotoxicity/NN
related/JJ
genes/NNS
than/IN
other/JJ
two/CD
statins/NNS
./.
====================
On/IN
the/DT
contrary/NN
,/,
lovastatin/NN
seemed/VBN
to/TO
have/VB
the/DT
least/JJS
effect/NN
on/IN
the/DT
expression/NN
of/IN
cytotxocity/NN
related/JJ
genes/NNS
./.
====================
Taken/VBN
together/RB
presented/VBN
results/VBZ
and/CC
previous/JJ
reports/NNS
,/,
the/DT
isolated/VBN
29/CD
probes/NNS
may/MD
serve/VB
as/IN
indicator/NN
genes/NNS
of/IN
statininduced/JJ
cytotoxicity/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
Since/IN
understanding/NN
the/DT
gene/NN
level/NN
mechanism/NN
of/IN
statincaused/VBN
hepatotoxicity/NN
was/VBD
main/JJ
purpose/NN
of/IN
this/DT
study/NN
,/,
selected/VBN
29/CD
probes/NNS
were/VBD
further/RBR
studied/VBN
./.
====================
First/RB
,/,
bi/NN
ological/JJ
function/NN
of/IN
each/DT
probe/NN
was/VBD
watched/VBN
for/IN
and/CC
corresponding/JJ
genes/NNS
were/VBD
isolated/VBN
./.
====================
From/IN
29/CD
probes/NNS
isolated/VBN
as/IN
stress/NN
markers/NNS
,/,
we/PRP
were/VBD
able/JJ
to/TO
identify/VB
21/CD
genes/NNS
whose/WP$
functions/NNS
are/VBP
annotated/VBN
(/(
Fig/NN
./.
====================
6/CD
)/)
./.
====================
It/PRP
was/VBD
remarked/VBN
that/DT
many/JJ
genes/NNS
are/VBP
known/VBN
to/TO
have/VB
their/PRP$
involvements/NNS
in/IN
inflammatory/JJ
or/CC
coagulation/NN
response/NN
such/JJ
as/IN
Ccl2/NN
,/,
Ccl7/NNP
,/,
Cxcl2/NN
,/,
F2r/NNP
,/,
F3/NN
and/CC
Crp/JJ
among/IN
annotated/JJ
genes/NNS
(/(
Bharadwaj/NNP
et/FW
al./FW
,/,
1999/CD
;/:
Hsu/NNP
et/FW
al./FW
,/,
2006/CD
;/:
Johnston/NNP
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
This/DT
observation/NN
concurred/VBD
with/IN
previously/RB
reported/VBD
clinical/JJ
effects/NNS
of/IN
statins/NNS
on/IN
inflammation/NN
or/CC
coagulation/NN
(/(
Dols/NNS
et/FW
al./FW
,/,
2009/CD
,/,
Maitland/CC
van/NN
der/NN
Zee/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
This/DT
implied/VBD
the/DT
involvement/NN
of/IN
these/DT
biological/JJ
pathways/NNS
in/IN
the/DT
observed/VBN
cytotoxic/JJ
effect/NN
of/IN
statins/NNS
on/IN
rat/NN
hepatocytes/NNS
./.
====================
Genes/NNS
involved/VBN
in/IN
cell/NN
proliferation/NN
were/VBD
also/RB
found/VBD
from/IN
the/DT
probe/NN
set/NN
,/,
for/IN
example/NN
Cdc42ep5/NN
predicted/VBN
and/CC
Tgfbeta2/NN
./.
====================
Beside/IN
genes/NNS
involved/VBN
in/IN
inflammation/NN
and/CC
proliferation/NN
,/,
a/DT
liver/NN
specific/JJ
gene/NN
,/,
Hnf4alpha/NN
was/VBD
isolated/VBN
./.
====================
Hnf4alpa/NN
is/VBZ
known/VBN
as/IN
a/DT
liver/NN
specific/JJ
transcription/NN
factor/NN
and/CC
reported/VBD
to/TO
have/VB
interaction/NN
with/IN
SMAD3/4/NN
protein/NN
in/IN
TGFbeta/NN
pathway/NN
(/(
Zannis/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
Hnf4alpha/NN
is/VBZ
also/RB
reported/VBD
to/TO
have/VB
implication/NN
in/IN
ER/NN
stress/NN
induced/VBN
acute/JJ
phase/NN
response/NN
in/IN
liver/NN
(/(
Luebke-Wheeler/NN
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Expression/NN
of/IN
annotated/JJ
21/CD
genes/NNS
was/VBD
further/RBR
examined/VBN
by/IN
RT-PCR/NN
to/TO
confirm/VB
microarray/NN
results/NNS
(/(
Fig/NN
./.
====================
6/CD
)/)
./.
====================
As/IN
seen/VBN
in/IN
Fig/NN
./.
====================
6/CD
,/,
some/DT
of/IN
them/PRP
(/(
Creb3I3/NN
,/,
Lamc2/NN
,/,
Flat/NN
and/CC
Oldlr1/NN
)/)
did/VBD
not/RB
produce/VB
any/DT
detectable/JJ
PCR/NN
products/NNS
but/CC
still/RB
most/JJS
of/IN
them/PRP
showed/VBD
certain/JJ
concordance/NN
to/TO
microarray/NN
results/NNS
./.
====================
In/IN
particular/JJ
,/,
genes/NNS
whose/WP$
functions/NNS
are/VBP
closely/RB
related/JJ
to/TO
liver/NN
toxicity/NN
such/JJ
as/IN
Crp/JJ
,/,
Hnf4alpha/NN
and/CC
TGFbeta2/NN
showed/VBD
very/RB
good/JJ
concordance/NN
between/IN
microarray/NN
and/CC
RT-PCR/NN
results/NNS
./.
====================
In/IN
the/DT
presented/VBN
study/NN
,/,
we/PRP
employed/VBD
gene/NN
expression/NN
profiling/VBG
techniques/NNS
and/CC
bioinformatic/JJ
analyses/NNS
to/TO
find/VB
a/DT
set/NN
of/IN
genes/NNS
which/WDT
may/MD
serve/VB
as/IN
indicators/NNS
for/IN
statininduced/JJ
liver/NN
toxicity/NN
./.
====================
Since/IN
statins/NNS
are/VBP
mostly/RB
widely/RB
used/VBN
drugs/NNS
in/IN
the/DT
world/NN
to/TO
treat/VB
pandemic/JJ
hyperchoresterolemia/NN
and/CC
have/VBP
been/VBN
reported/VBN
recurrently/RB
to/TO
have/VB
liver/NN
toxicity/NN
in/IN
clinical/JJ
uses/VBZ
,/,
finding/VBG
genes/NNS
which/WDT
could/MD
explain/VB
underlying/VBG
mechanism/NN
and/CC
serve/VBP
as/IN
indicator/NN
is/VBZ
of/IN
most/JJS
interest/RB
in/IN
drug/NN
development/NN
and/CC
regulation/NN
field/NN
./.
====================
By/IN
combining/VBG
an/DT
in/FW
vitro/FW
model/NN
system/NN
and/CC
microarray/NN
techniques/NNS
,/,
we/PRP
were/VBD
able/JJ
to/TO
isolate/VB
genes/NNS
whose/WP$
expressions/NNS
were/VBD
commonly/RB
modulated/VBN
by/IN
statins/NNS
and/CC
which/WDT
also/RB
had/VBD
biological/JJ
functions/NNS
related/JJ
to/TO
response/NN
to/TO
stress/NN
./.
====================
It/PRP
is/VBZ
still/RB
too/RB
early/JJ
to/TO
say/VB
that/DT
the/DT
genes/NNS
listed/VBN
in/IN
this/DT
work/NN
could/MD
serve/VB
as/IN
biomarkers/NNS
for/IN
statininduced/JJ
liver/NN
toxicity/NN
but/CC
they/PRP
demonstrated/VBD
the/DT
potential/JJ
of/IN
gene/NN
expression/NN
analysis/NN
for/IN
understanding/VBG
and/CC
predicting/VBG
certain/JJ
effects/NNS
of/IN
drugs/NNS
such/JJ
as/IN
statininduced/VBN
cytotoxicity/NN
in/IN
rat/NN
primary/JJ
hepatocytes/NNS
./.
====================
To/TO
further/RBR
validate/NN
current/JJ
findings/NNS
and/CC
make/VBP
applicable/JJ
to/TO
clinical/JJ
purpose/NN
,/,
it/PRP
will/MD
necessary/JJ
to/TO
compare/VB
biomarkers/NNS
from/IN
rat/NN
primary/JJ
hepatocytes/NNS
with/IN
those/DT
from/IN
human/JJ
primary/JJ
hepatocytes/NNS
or/CC
those/DT
from/IN
human/JJ
liver/NN
tissues/NNS
(/(
Hart/NN
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
